San Francisco startup Structure Therapeutics is likewise focusing on an oral, at the time-every day GLP-1 drug referred to as GSBR-1290—the drug surpassed Wall Street’s expectations in June when a mid-phase examine showed common weight loss of about six% and it strategies to start out Yet another mid-stage trial toward the top of this yr—that